Menu
My Activity Hub
Podcasts
Videos
Pricing
Feedback
Tutoring
Sign Up
Log In
My Activity Hub
Podcasts
Videos
How it works
Pricing
Tutoring
Sign Up
Log In
CME
Risk-Stratification in Newly Diagnosed CLL
0 secs; August 15, 2024
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
0 secs; August 15, 2024
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
0 secs; August 14, 2024
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
0 secs; August 12, 2024
Case in Point: The Use of GnRH Antagonists Pre- and/or Post-Surgery and the Potential Consequences of Repeat Surgery
0 secs; August 08, 2024
Creating a Practice Environment That Enhances Healthcare Equality for All Patients
0 secs; August 08, 2024
Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey
0 secs; August 08, 2024
Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis
0 secs; August 08, 2024
The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences
0 secs; August 08, 2024
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
0 secs; August 07, 2024
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
0 secs; August 07, 2024
Burden of Disease – Narcolepsy
0 secs; July 30, 2024
Case Study: Management of Narcolepsy
0 secs; July 30, 2024
Challenges in Recognizing and Diagnosing Narcolepsy
0 secs; July 30, 2024
Expert Approaches to the Diagnosis of Narcolepsy
0 secs; July 30, 2024
Expert Approaches to the Management of Narcolepsy
0 secs; July 30, 2024
Novel and Emerging Treatment Strategies for Narcolepsy
0 secs; July 30, 2024
Psychosocial Impacts- Impact on Employment and Healthcare Costs
0 secs; July 30, 2024
Beyond Guesswork: Validated Methods for MCI Assessment in Alzheimer's Diagnosis
0 secs; July 24, 2024
Breaking Ground: The Latest Data on AD Disease-Modifying Therapies
0 secs; July 24, 2024
Comparative Efficacy: SubQ vs. Intravenous DMTs in Alzheimer's Disease
0 secs; July 24, 2024
Dementia on a Spectrum: Preclinical Stages of MCI in AD
0 secs; July 24, 2024
Future Frontiers: The Future Landscape of Alzheimer's Therapeutics
0 secs; July 24, 2024
Inequity and Illness: Understanding MCI Disease Course and Severity for Racial Minorities
0 secs; July 24, 2024
Markers of Memory: Pathological Biomarkers of Clinical MCI Due to AD
0 secs; July 24, 2024
Precision Imaging: MRI's Critical Role in Early MCI AD Diagnosis
0 secs; July 24, 2024
The Subtle Onset: Understanding Early MCI AD Symptoms
0 secs; July 24, 2024
Therapeutic Insights: Navigating the Use and Challenges of Disease-Modifying Therapies
0 secs; July 24, 2024
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
0 secs; July 22, 2024
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 Ă— 109/L?
0 secs; July 18, 2024
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
0 secs; July 18, 2024
Exploring Autophagy through Sigma-1 Receptor Activation: Innovative Therapeutics for Alzheimer's Disease Beyond Amyloid Pathways
0 secs; July 18, 2024
How and When to Manage Ruxolitinib Failure
0 secs; July 18, 2024
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
0 secs; July 18, 2024
Improving Transfusion Independence With JAK Inhibitor Therapy
0 secs; July 18, 2024
Managing Myelofibrosis-Associated Anemia
0 secs; July 18, 2024
Managing Myelofibrosis-Associated Thrombocytopenia
0 secs; July 18, 2024
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
0 secs; July 18, 2024
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
0 secs; July 18, 2024
Real-World Experience With Pacritinib in the US
0 secs; July 18, 2024
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
0 secs; July 18, 2024
Advancements in GU Cancers: Key Data from AUA 2024
0 secs; July 17, 2024
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
0 secs; July 17, 2024
Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
0 secs; July 16, 2024
Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices
0 secs; July 16, 2024
Current Unmet Needs in the Field of Unresectable HCC
0 secs; July 16, 2024
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
0 secs; July 16, 2024
Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC
0 secs; July 16, 2024
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
0 secs; July 16, 2024
Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC
0 secs; July 16, 2024
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
0 secs; July 16, 2024
Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
0 secs; July 16, 2024
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGF Inhibitors
0 secs; July 16, 2024
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
0 secs; July 16, 2024
Advancing Care: Innovative Therapies for Residual Symptoms in MDD
0 secs; July 14, 2024
Beyond Monotherapy: Augmentation Strategies to Combat the Residual Symptoms of MDD
0 secs; July 14, 2024
Diagnostic Hurdles: Recognizing and Addressing Treatment-Resistant Depression
0 secs; July 14, 2024
Empowering Patients: Enhancing Engagement for Better MDD Outcomes
0 secs; July 14, 2024
Hidden in Plain Sight: Overlapping Symptoms That Challenge a Diagnosis of MDD
0 secs; July 14, 2024
Navigating Traditional Treatment Options: Current Therapeutic Strategies and Their Limitations for Residual Symptoms in MDD
0 secs; July 14, 2024
No Symptom Left Behind: Utilizing Standardized Tools to Detect and Manage Residual Depression Symptoms
0 secs; July 14, 2024
Personalized Care: Tailoring Treatment Plans for Residual Symptoms in MDD
0 secs; July 14, 2024
The Art of Adherence: Clinician Strategies for Enhancing Medication Compliance
0 secs; July 14, 2024
Beneath the Surface: Understanding the Pathophysiology of Residual MDD Symptoms
0 secs; July 14, 2024
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
0 secs; July 09, 2024
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
12 mins; April 14, 2024
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
0 secs; January 30, 2024
Challenging TAVR Cases
0 secs; January 30, 2024
Contemporary TAVR Outcomes in Patients with Small Aortic Annulus: A Review of Recent Trial Data
0 secs; January 30, 2024
Cutting-Edge Trials: TAVR for Small Aortic Annuli
0 secs; January 30, 2024
It’s All About Patient Identification
0 secs; January 30, 2024
New Hope for TAVR: Overcoming Challenges for Women & Patients With Small Annuli
0 secs; January 30, 2024
New TAVR Data – New TAVR Talk Track
0 secs; January 30, 2024
Putting Data into Clinical Practice
0 secs; January 30, 2024
Advances in Minimally Invasive Screening for Lung Cancer
0 secs; November 09, 2023
Can You Manage Patients With Uncontrolled Gout More Effectively?
5 mins; October 23, 2023
Center of the Target: Which Patients Are Most Likely to Develop Gout?
5 mins; October 23, 2023
Gout Beyond the Joints: What’s the Hidden Danger?
3 mins; October 23, 2023
Is Gout Hiding in the Nephrology Clinic?
5 mins; October 23, 2023
Is Managing Gout in the Nephrology Clinic a Challenge?
4 mins; October 23, 2023
Should We Look for Gout in the Cardiology Clinic?
4 mins; October 23, 2023
Treat or Refer: Who Is Responsible for Managing Gout?
5 mins; October 23, 2023
What Are the Emerging Therapies for Managing Gout?
5 mins; October 23, 2023
What’s New About Gout? Nephrology Perspective
5 mins; October 23, 2023
What’s New About Gout? Rheumatology Perspective
5 mins; October 23, 2023
Improving Symptoms in Patients with HFrEF Using Novel Device Therapy
13 mins; August 06, 2023
Antibody-Drug Conjugates in FL
0 secs; July 14, 2023
Application of Data from the ECHELON-1 Trial
0 secs; July 14, 2023
Bispecific Antibodies in FL
0 secs; July 14, 2023
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
0 secs; July 14, 2023
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
0 secs; July 14, 2023
Individualizing Frontline Treatment
0 secs; July 14, 2023
Late-Stage Bispecifics and ADCs in DLBCL
0 secs; July 14, 2023
NCCN Guideline Updates in DLBCL
0 secs; July 14, 2023
Patient Selection for ADCs in First-Line DLBCL
0 secs; July 14, 2023
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
14 mins; April 30, 2023
Cardio-Oncology: Key Clinical Data from ACC.23
3 mins; March 22, 2023
Case Management Strategies for Patients with ADPKD – Part 2
26 mins; January 30, 2023
Case Management Strategies for Patients with ADPKD – Part 1
25 mins; January 23, 2023
Prognostic Tools in the Management of ADPKD
24 mins; December 11, 2022
Click here to see more
‹ Prev
1
2
3
4
5
6
7
8
Next ›
